Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05411484
PHASE2

Investigation of Laser Assisted Drug Delivery of NanoDOX®

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

This is a self-controlled single-site study of healthy subjects receiving an ablative fractional CO2 (carbon dioxide) laser procedure followed by topical application of NanoDOX® Hydrogel (1% doxycycline). The study includes skin biopsies to evaluate the effects of NanoDOX® Doxycycline Monohydrate Gel on wound healing after the ablative laser procedure. Study subjects will be asked to do 2 visits of 4 hours in total over approximately 1 week. An optional third visit will take place approximately 6 weeks after Visit 1. In this study, 20 subjects are expected to enroll with a goal of 12 healthy subjects to enroll and complete the study.

Official title: Self-controlled, Single-site Trial Investigation of Laser Assisted Drug Delivery of NanoDOX®

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2023-11-29

Completion Date

2026-04

Last Updated

2025-10-28

Healthy Volunteers

Yes

Interventions

DRUG

NanoDOX® Hydrogel

NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin

DEVICE

CO2 Ablative Fractional Laser

CO2 Ablative Fractional Laser will be applied to healthy skin areas

Locations (1)

MGH Clinical Unit for Research Trials And Outcome

Boston, Massachusetts, United States